Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by

Status Completed

Clinical Trial Summary

With our retrospective study the investigators show the limitations of the posterior retroperitoneal adrenalectomy by analyzing anatomical parameters.

The investigators compared the data from one patient who underwent a conversion with 13 patients without a conversion. Furthermore, they explored the influence of these parameters on the operation time and excluded the patient who had a conversion from this analysis.

The investigators hypothesize that by determining anatomical characteristics on cross-sectional imaging (CT or MRI), they can show the limitations of the posterior retroperitoneal adrenalectomy to prevent patients from being converted to lateral transperitoneal adrenalectomy.

Clinical Trial Description

Minimally invasive adrenalectomy has become the gold standard for the surgical treatment of small, benign adrenal lesions. In addition to the common laparoscopic lateral transperitoneal adrenalectomy, the posterior retroperitoneal adrenalectomy is becoming increasingly important.

To date, there is no consensus regarding the preferred approach in the resection of benign adrenal tumors. A comprehensive adrenal tumor program should be able to offer both options, however, patient selection criteria for a given approach have not yet been defined. The choice between lateral transperitoneal adrenalectomy and posterior retroperitoneal adrenalectomy is relevant for patients with unilateral tumors < 6-7 cm and without previous abdominal surgery.

The aim of this study was to determine the limits of posterior retroperitoneal adrenalectomy using anatomical parameters to enable the preferred access to be chosen preoperatively to prevent conversion. In addition, the investigators describe the relationship between these parameters and the operation time to find a measure of the degree of technical difficulty. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04071561
Study type	Observational
Source	University of Basel
Contact
Status	Completed
Phase
Start date	November 19, 2018
Completion date	May 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06050057` - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting	`NCT05636618` - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors	Phase 1/Phase 2
Terminated	`NCT03986593` - Cryoablation of Bone Metastases From Endocrine Tumors	N/A
Terminated	`NCT05948137` - F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
Completed	`NCT00970970` - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Active, not recruiting	`NCT00436735` - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors	Phase 1
Recruiting	`NCT00669266` - Adrenal Tumors - Pathogenesis and Therapy
Recruiting	`NCT05069220` - 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor	Early Phase 1
Recruiting	`NCT06062082` - Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma
Recruiting	`NCT04573816` - Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
Active, not recruiting	`NCT04400474` - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2
Not yet recruiting	`NCT06045260` - "Receptor Radionuclide Therapy With 177Lu-DOTATOC	Phase 2
Completed	`NCT00001147` - Blood Sampling for Neurochemical and Genetic Testing	N/A
Terminated	`NCT00002947` - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer	Phase 1
Completed	`NCT00001229` - Diagnosis and Treatment of Pheochromocytoma	N/A
Completed	`NCT01967576` - Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma	Phase 2
Recruiting	`NCT03160274` - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Recruiting	`NCT03206060` - Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma	Phase 2
Not yet recruiting	`NCT04788927` - Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Enrolling by invitation	`NCT03474237` - A Prospective Cohort Study for Patients With Adrenal Diseases

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical Conditions

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms